Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Jan;235(1):10-26.
doi: 10.1097/00000658-200201000-00003.

Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years

Attiqa N Mirza  1 , Nadeem Q Mirza, Georges Vlastos, S Eva Singletary
Affiliations
Review

Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years

Attiqa N Mirza et al. Ann Surg. 2002 Jan.

Abstract

Objective: To review the published literature on prognostic factors in patients with node-negative breast cancer, focusing principally on recent studies with large sample sizes and extended follow-up periods.

Summary background data: Although numerous studies have examined prognostic factors in patients with breast cancer, relatively few have dealt specifically with node-negative disease, and interpretation has been limited by small sample size and limited follow-up times.

Methods: A review of the Medline database from 1996 to 2000 was undertaken, with additional papers published before 1996 identified through review articles. For inclusion in the analysis, papers needed to meet the following core criteria: 200 or more node-negative patients with invasive breast carcinoma; median follow-up time at least 5 years; method of testing and cut-off points specified; overall survival and/or disease-free survival specified; and relative risk or statistical probability values given for comparisons.

Results: Three or more papers that met the core criteria were retrieved for each of 11 potential prognostic factors. Of these, tumor size, tumor grade, cathepsin-D, Ki-67, S-phase fraction, mitotic index, and vascular invasion showed a significant association with survival outcomes; HER2/neu and DNA ploidy showed no significant association; and estrogen receptor status and p53 showed mixed results. Lack of standardization in measurement techniques for many of the markers, including cathepsin-D, Ki-67, HER2/neu, and p53, limited their current clinical usefulness.

Conclusions: In large studies with extended follow-up periods, tumor size, tumor grade, cathepsin-D, Ki-67, S-phase fraction, mitotic index, and vascular invasion showed a significant association with survival outcome measures in patients with early-stage node-negative breast cancer. Because of technical difficulties and variations in the measurement of many of these factors, tumor size and tumor grade remain the only markers that currently have broad clinical usefulness for this patient group.

PubMed Disclaimer

References

    1. Elledge RM, McGuire WL. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Annu Rev Med 1993; 44: 201–220. - PubMed
    1. Rosen PP, Groshen S, Saigo PE, et al. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989; 7: 355–366. - PubMed
    1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181–187. - PubMed
    1. Fitzgibbons PL, Page KL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999; Arch Pathol Lab Med 2000; 124: 966–975. - PubMed
    1. Harvey JN, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–1481. - PubMed

MeSH terms